It is known that women are often underrepresented, or even excluded, in randomized clinical trials, the results of which consequently may not be entirely reproduced in the general population. At the same time, however, sex-based differences in various manifestations of cardiovascular disease are increasingly recognized. Consequently, registries and/or retrospective analyses focusing on sex-related diversity have been widely used in the last years [1–3].
